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Informing potential participants about the aims and pro-
cedures of a trial is mandatory when seeking their consent.
A description of the potential benefits and harms of the inter-
vention and control conditions is an integral part of the infor-
mation that should be provided. The World Medical
Association’s Declaration of Helsinki from 1964 [1] is the
most often used guideline when it comes to the content of
informed consent. It states that ‘‘the nature, the purpose
and the risk of clinical research must be explained to the sub-
ject by the doctor.’’ In addition, the Declaration of Helsinki
explicitly states that consent should, as a rule, be obtained
in writing. Research ethics committees are used to check
whether the informed consent procedures proposed by re-
searchers adhere to this general guideline. Current practice
in obtaining informed consent seems to have been shaped
by emphasis on the legal duty of disclosure; consent is seen
as an action, concluded by signing a form [2]. In linewith this
administrative attitude toward informed consent, the proced-
ure is standardly reported in a research article.
However, the exact information that is given to potential
participants is often not understood by them [3,4]. At the
same time, this information affects their decision to accept
or refuse the invitation to take part in a trial [5e7], for
example, because of the description of the expected treat-
ment effect [8] or the extent to which pain is emphasized
in the provided information [9]. Furthermore, the informa-
tion may also affect the behavior of participants during theFunding: The authors have not received any funding for the current
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0895-4356/ 2019 Elsevier Inc. All rights reserved.trial (in particular regarding trials where participants cannot
be blinded), for example, dissatisfaction with not receiving
a potentially beneficial treatment or loyalty to those
providing the treatment [10], which might also lead to
dropout [11]. It is therefore important to know, when inter-
preting findings from a trial, how participants were
informed about their participation.
Guidelines such as Consolidated Standards of Reporting
Trials (CONSORT) [12] have been developed to improve
the reporting of trials. Implementation of such guidelines
and endorsement by leading medical journal editorial orga-
nizations have led to better reporting of trials, although the
current reporting is still not optimal [13e17]. Because the
first version of CONSORT, which was published in 1996
[18], several updates and extensions have been published
(www.consort-statement.org). Until to date, however, these
guidelines do not include a statement with regard to the re-
porting of the informed consent procedure of trials. This
may be a reason why details about informed consent pro-
cedures of randomized controlled trials are currently poorly
reported as our research shows.
We used the data frame of a systematic review including
a random sample of 100 medical trials [19] to assess which
information on informed consent procedures is commonly
reported. Whereas almost all reports (92/100) included a
statement that informed consent was sought from partici-
pants, only very few (6/100) reports included some details
about how exactly participants were informed. However,
the given information was often very brief (see examples
in Box 1). No report (0/100) referred to a publication with
additional detailed information or provided the original
participant information as supplementary material (full data
from this analysis can be found on the Open Science
Framework: https://osf.io/fx3m7/).
We argue that details about informed consent procedures of
randomized controlled trials should be reported transparently.
We propose that essential features of the information for par-
ticipants arevery briefly summarized in themethods section of
Box 1 Examples of the reporting of details about
the informed consent procedure in trial
publications
‘‘Each patient signed a consent form before being
included in the study, and all patients were informed
about both arms of the trial (CPAP and sham CPAP as
placebodCPAP at a very low pressure (!1 cm H20)
without any known therapeutic effect).’’ [20].
‘‘All eligible mothers were informed by the
fieldworkers about the overall aims of the study
(advice on feeding of infants and its effects on the
child’s health) as well as all research procedures,
including use of a questionnaire, anthropometric
and blood hemoglobin measurement, dental examina-
tion, and differences between the intervention and
control groups.’’ [21].
‘‘To ensure equipoise, the description of the study
to patients and their physicians emphasized the
possible benefits and limitations of both the interven-
tion and usual care conditions.’’ [22].
134 D. Kotz et al. / Journal of Clinical Epidemiology 109 (2019) 133e135a trial report and that the full, original participant information
letter (and ideally also an English translation if necessary) is
published alongside the report as supplementary material or
using platforms such as the Open Science Framework. This
fits with the currentmove toward amore open research culture
in which transparency, openness, and reproducibility are vital
features [23e26]. We further recommend including a respec-
tive statement in a future version of CONSORT and related
guidelines on the reporting of detailed information about the
informed consent procedure, in particular how potential ben-
efits and harms of the intervention and control conditionswere
communicated to participants.Acknowledgments
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